Edition:
India

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

5.63USD
20 Jul 2018
Change (% chg)

$0.03 (+0.54%)
Prev Close
$5.60
Open
$5.63
Day's High
$5.63
Day's Low
$5.63
Volume
950
Avg. Vol
49,972
52-wk High
$11.65
52-wk Low
$2.65

Select another date:

Tue, Apr 10 2018

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

* CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan

* CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

* CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA

BRIEF-Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co

* CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION Source text: (http://bit.ly/2ER7sY9) Further company coverage:

Select another date: